Corvus Pharmaceuticals reports clinical, financing, governance, and financial updates for a clinical-stage biopharmaceutical company developing ITK inhibition as an immunotherapy approach for immune diseases and cancer. Its lead candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit interleukin-2-inducible T cell kinase, a protein involved in T cell activation, signaling, differentiation, and function.
Recurring company news centers on soquelitinib clinical development in relapsed/refractory peripheral T cell lymphoma and atopic dermatitis, including immunologic and biomarker data presented at medical meetings. Updates also cover business results, public equity financing for research and development, board composition, and other clinical-stage pipeline disclosures.
Corvus Pharmaceuticals announced the approval of an IND application to initiate a Phase 1/1b clinical trial for mupadolimab in China, in partnership with Angel Pharmaceuticals. Mupadolimab targets CD73 to activate immune responses in patients with relapsed refractory non-small cell lung cancer (NSCLC) and head and neck squamous cell cancers (HNSCC). The trial aims to evaluate the drug’s safety, pharmacokinetics, and efficacy, with plans for a subsequent randomized Phase 2 trial in combination with pembrolizumab and chemotherapy.
Corvus Pharmaceuticals (Nasdaq: CRVS) has announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CEO Richard A. Miller will present a pre-recorded corporate overview, available on-demand starting September 12 at 7:00 am ET. The presentation will be accessible for 90 days on the Corvus investor relations webpage. Corvus focuses on developing innovative treatments for T-cell lymphomas, notably its lead candidate CPI-818 and other programs such as ciforadenant and mupadolimab.
Corvus Pharmaceuticals (CRVS) provided a business update and financial results for Q2 2022. The company is prioritizing CPI-818 for T cell lymphomas and related autoimmune diseases, showing promising early clinical data. Additionally, it plans a Phase 2 trial for ciforadenant in metastatic renal cell cancer with the Kidney Cancer Clinical Trials Consortium in Q3 2022. However, development of mupadolimab for lung cancer is paused to focus resources. As of June 30, 2022, cash reserves amounted to $56.7 million, projected to fund operations into early 2024.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced a conference call and webcast scheduled for August 8, 2022, at 4:30 PM ET to report second quarter 2022 financial results and provide a business update. The call can be accessed via phone or through a live webcast on Corvus' investor relations page, with a replay available for 90 days. Corvus focuses on developing novel therapies, including mupadolimab (CPI-006) and CPI-818, for the treatment of various cancers.
Corvus Pharmaceuticals (Nasdaq: CRVS) has appointed Dr. James Rosenbaum as Senior Vice President of Research to lead the development of CPI-818, an ITK inhibitor aimed at treating immune disorders and T cell lymphomas. CPI-818 is currently in a Phase 1/1b clinical trial with promising interim results that may support future Phase 2 trials. Dr. Rosenbaum brings extensive experience in immunology and autoimmune diseases, enhancing the company's research capabilities in clinical and preclinical settings.
Corvus Pharmaceuticals (Nasdaq: CRVS) hosted an R&D Symposium showcasing interim data from the Phase 1/1b study of CPI-818 in patients with relapsed T cell lymphomas. The trial identified a 200 mg optimal dose, with notable patient responses, including a complete remission lasting 19 months. Key findings indicate CPI-818's potential in enhancing anti-tumor immunity without directly killing cancer cells. The company plans to expand its study, with future data releases anticipated, and aims to initiate a global Phase 2 trial if trends continue.
Corvus Pharmaceuticals (CRVS) reported its Q1 2022 financial results, revealing cash reserves of $62.9 million, down from $69.5 million at the end of 2021. The net loss narrowed to $8.3 million compared to $11.6 million in Q1 2021. The company is advancing three clinical candidates, including mupadolimab for non-small cell lung cancer and ciforadenant for renal cell cancer, with trials set to start later in the year. Corvus will host an R&D Symposium on May 10, 2022, to discuss these clinical efforts.
Corvus Pharmaceuticals will host an R&D Symposium on May 10, 2022, in New York City, from 9:00 AM to 11:30 AM ET. The event aims to update on three clinical programs: anti-CD73 (mupadolimab), adenosine 2A receptor antagonist (ciforadenant), and ITK inhibitor (CPI-818) in T cell lymphomas. The symposium will feature insights from Corvus President Richard A. Miller, M.D., along with expert speakers from Stanford University and Angel Pharmaceuticals. The event will be webcast live and available for replay for 90 days.
Corvus Pharmaceuticals (Nasdaq: CRVS) provided a business update and 2021 financial results, highlighting progress in clinical programs targeting cancer. The firm plans a Phase 2 trial for mupadolimab in advanced non-small cell lung cancer and has expanded CPI-818 trials in China for T cell lymphomas. Cash reserves increased to $69.5 million from $44.3 million year-over-year, with a projected net cash usage of $34-$36 million in 2022. However, the net loss for 2021 was $43.2 million, a decline from a prior gain in 2020, primarily due to the absence of significant one-time gains.
Corvus Pharmaceuticals (Nasdaq: CRVS) will hold a conference call on March 10, 2022, at 4:30 pm ET to discuss business updates and report its Q4 and full year 2021 financial results. Investors can join the call by dialing 1-877-407-0784 for domestic or 1-201-689-8560 for international access. Registration requires the conference ID 13727689. The call will also be available via webcast, with a replay accessible on the company’s website for 90 days.